Aerie Pharmaceuticals completes enrollment of mercury 2 phase 3 registration trial
Aerie Pharma announced completion of patient enrollment in the Company's second Phase 3 registration trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower IOP in patients with glaucoma. December 07, 2016